ReviewAntimicrobial agents and chemotherapy1993
Antimicrobial strategies in the care of organ transplant recipients.
Review in Antimicrobial agents and chemotherapy, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 91 citations in OpenAlex.
- Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients.Journal of clinical microbiology · 2000Trial
- Review
- The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients: A review of the British Columbia experience.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2005Article
- Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.Current infectious disease reports · 2002Article
- Catheter-associated urinary infection in kidney post-transplant patients.Sao Paulo medical journal = Revista paulista de medicina · 2001Article
- New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.Clinical microbiology reviews · 2000Review
- Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients.Journal of clinical microbiology · 1998Article
- Evaluation of PCR primers for early diagnosis of cytomegalovirus infection following liver transplantation.Journal of clinical microbiology · 1998Article
- [Preventive antimycotic therapy of neutropenic and immunosuppressed patients].Medizinische Klinik (Munich, Germany : 1983) · 1997Review
- Infections in solid-organ transplant recipients.Clinical microbiology reviews · 1997Review
- Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.Drugs · 1996Review
- Detection of cytomegalovirus DNA in sera of liver transplant recipients.Journal of clinical microbiology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the early days of transplantation, infection has been a major consequence of antirejection immunosuppressive therapy. Increasingly effective prophylactic and preemptive strategies are being developed to prevent the infectious consequences of immunosuppressive therapy. Although the data base is incomplete and there remains a compelling need for well-designed, randomized, comparative trials, the potential for controlling life-threatening viral, bacterial, fungal, and protozoal infections exists. The cornerstone of this effort is the recognition that effective immunosuppressive strategies require an antimicrobial program to make them safe and that such an antimicrobial program needs to be individualized in order to be appropriately matched with the needs of the antirejection program. Thus, escalation and de-escalation of the antimicrobial program should be carried out to match the immunosuppressive program. Infection and rejection remain closely intertwined, linked by the immunosuppressive program that is prescribed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.